Unquote: DACH – “Concerning prognoses for German healthcare”

The private equity news portal Unquote evaluates the effects of the new German Scheduling and Supply Act and refers to the opportunities and risks of the global medical technology market. Despite tougher regulations, experts do not expect an economic slowdown for the medical technology, life science and biotechnology industries. Dr. Andre Zimmermann, Partner at SHS Gesellschaft für Beteiligungsmanagement, sees the increasing demographic development in industrialized countries and the increasing demand for medical technology in China and India as a driving force for the long-term growth of the sector. In addition, Dr. Zimmermann explains that the resilience of the sector to macroeconomic shocks is above average and thus offers high returns at comparatively low risk. The attractive conditions of investments in the medical technology sector are also reflected in the high company valuations, which according to experts average 12-14x EBITDA.